# Mesoblast Ryoncil commercial development

> Live situation record from CLSTR: https://clstr.news/situations/mesoblast-ryoncil-commercial-development
> Updated: 2026-10-15T23:44:05.000Z. Sources: 4. Developments: 2.

Mesoblast Limited has achieved regulatory and financial milestones regarding its Ryoncil product, an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease.

In late September 2026, the U.S. Food and Drug Administration approved a new potency assay for Ryoncil known as the T-cell Proliferation Inhibition BioAssay (TIBA). This assay is intended to ensure consistent quality and potency during manufacturing scale-up and production changes.

By mid-October 2026, the company reported significant financial growth for the first fiscal quarter ending September 30, 2026. Mesoblast saw a 44% increase in net revenue from Ryoncil, totaling US$28 million, alongside an 85% improvement in net operating cash spend. The company noted a high number of new patient starts in September and plans to expand adoption across its 54 treatment sites.

## Claims

- Mesoblast reported its first fiscal quarter results for the period ending September 30, 2026. (corroborated by 3 sources)
- Net revenue from Ryoncil sales increased 44% to US$28 million compared to US$19 million in the prior year period. (corroborated by 3 sources)
- Net operating cash spend improved by 85%, reducing to US$2.3 million from US$14.9 million in the prior year period. (corroborated by 3 sources)
- The company recorded a cash position of US$99 million as of September 30, 2026. (corroborated by 3 sources)
- Ryoncil is the only FDA-approved mesenchymal stromal cell product for children under age 12 with steroid-refractory acute graft-versus-host disease. (corroborated by 3 sources)
- Ryoncil adoption is occurring across 54 onboarded treatment sites. (corroborated by 3 sources)

## Timeline

### 2026-10-15: Mesoblast reports 44% revenue surge in Ryoncil sales for Q1 FY26

Mesoblast reported a 44% increase in Ryoncil revenue to US$28 million and an 85% improvement in cash spend for Q1 FY26, ending the period with US$99 million in cash.

3 sources. https://clstr.news/cluster/mesoblast-reports-44-revenue-surge-in-ryoncil-sales-for-q1-fy26

### 2026-09-24: Mesoblast secures FDA approval for new Ryoncil potency assay

Mesoblast has secured FDA approval for a new T-cell Proliferation Inhibition BioAssay (TIBA) to monitor the potency and stability of its Ryoncil cell therapy during commercial manufacturing.

4 sources. https://clstr.news/cluster/mesoblast-secures-fda-approval-for-new-ryoncil-potency-assay

---
Cite as: Mesoblast Ryoncil commercial development. CLSTR, https://clstr.news/situations/mesoblast-ryoncil-commercial-development